Atezolizumab Regimen Fails to Extend PFS in Newly Diagnosed Ovarian Cancer

May 24, 2021 3:00 pm

By Jennifer Southall

The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical OncologyRead more

Immunotherapy Falls Short Again in Ovarian Cancer

September 23, 2020 6:00 pm

No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab.

By Charles Bankhead

An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.… Read more